Split daily doses of hydroxycarbamide for children with sickle cell disease
Tests split-dose hydroxycarbamide in children with sickle cell disease.
Key facts
- Who runs it
- Theravia
- Where
- Cayenne, French GuianaSee the siteAlso in 1 other country, 6 sites
- Trial code
- Registry title
- Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Started
- 21 Jan 2025
- Expected to end
- Feb 2028
- Type of study
- Interventional
- Treatments tested
- Hydroxycarbamid
- Record updated
- 1 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children with sickle cell disease (HbSS or HbSβ0) aged 9 months to 11 years who have never taken hydroxycarbamide. They take it twice a day for 12 months.
- Age
- 9 months to 11 years
- Sex
- Girls and boys can join.
- Disease stage
- Sickle cell disease of type HbSS or HbSβ0. Children over 18 months need a transcranial Doppler in the last 12 months showing low risk for stroke.
- Earlier treatment
- Must never have taken hydroxycarbamide. No regular blood transfusions or any transfusion in the last 3 months. No other treatments that change sickle cell disease.
- Biomarker or test result
- Absolute neutrophil count ≥ 1.0x109/L, platelets ≥ 75x109/L and haemoglobin > 5.5 g/dL.
Main reasons for not taking part
- Took part in another drug study in the last 4 weeks
- Chronic kidney disease stage 3, 4 or 5
- Known HIV, hepatitis B or hepatitis C infection
- Stroke or bleeding inside the skull in the past, or an unchecked nervous system finding in the last 12 months
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Written informed consent, signed and dated by both parents or by the legally acceptable representative(s) of the children, and, if possible, assent from the children,
- HbSS or HbSβ0 SCD,
- Aged between 9 months and 11 years old,
- Hydroxycarbamide naïve,
- Parent(s) or legally acceptable representative(s) capable of communicating with the investigator and understanding the requirements and constraints of the study protocol and willing to comply with the study requirements,
- Contraception criterion, if applicable: for patients who are sexually active
- Affiliated to a social security plan or beneficiary of a similar insurance plan,
- Patient must meet the following laboratory values : Absolute Neutrophil Count ≥ 1.0x109/L, Platelets ≥ 75x109/L and Haemoglobin (Hgb) > 5.5 g/dL,
- Transcranial Doppler (TCD) in the last 12 months indicating low risk for stroke is required for children over 18 months of age
Who cannot take part
- Patients treated with other SCD-modifying therapies,
- Patient with a stage 3, 4 or 5 chronic kidney disease,
- Patients known to be infected with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus,
- Known hypersensitivity or allergy to the excipients,
- Any surgical or medical condition or any significant illness that, in the opinion of the investigator, constitutes a risk or a contraindication to the participation of the patient to the study, or that may interfere with the objectives, conduct or evaluation of the study,
- Any documented history of a clinical stroke or intracranial haemorrhage, or an uninvestigated neurologic finding within the past 12 months
- Participation in any other clinical study for any other pharmaceutical product within 4 weeks preceding the inclusion visit,
- Patients who have had chronic blood transfusion or transfusion in the last 3 months preceding the inclusion visit,
- Female patients who are pregnant or lactating,
Where in French Guiana
Also in 1 other country, 6 sites
- Centre Hospitalier de CayenneCayenne, French GuianaContact: Narcisse Elenga, MD, PhDTaking people
About the trial
What the trial wants to find out
The purpose of this interventional, phase II, national, multicentric, non-randomised, open-label study is to evaluate the pharmacokinetics (PK), efficacy and safety of Hydroxycarbamide Paediatric dispersible tablets with a twice daily dosing regimen in children with Sickle Celle Disease between 9 months to 11 years of age.
Read full original descriptionShow less
Participants will:
* Take Hydroxycarbamide twice a day every day for 12 months * Visit the clinic at screening, baseline, 1, 3, 6, 9 and 12 months
The group in the trial
- Hydroxycarbamide Pediatric dispersible tabletTreatment being tested
Hydroxycarbamide Pediatric dispersible tablet will be administered twice daily during 12 months.
Treatment: Hydroxycarbamid
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease: a Single-group, Non-randomised, Open-label Study (KID-BID)
- Plain-language title
- Split daily doses of hydroxycarbamide for children with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 1 October 2026